F/M Emerald Life Sciences Innovation ETF (LFSC)
NASDAQ: LFSC · Real-Time Price · USD
37.05
-0.59 (-1.57%)
Apr 28, 2026, 4:00 PM EDT - Market closed
-1.57% (1D)
| Assets | $100.45M |
| Expense Ratio | 0.54% |
| PE Ratio | n/a |
| Shares Out | 2.67M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | n/a |
| Volume | 1,072 |
| Open | 36.95 |
| Previous Close | 37.64 |
| Day's Range | 36.95 - 37.05 |
| 52-Week Low | n/a |
| 52-Week High | n/a |
| Beta | n/a |
| Holdings | 44 |
| Inception Date | Oct 31, 2024 |
About LFSC
Fund Home PageThe F/M Emerald Life Sciences Innovation ETF (LFSC) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed ETF that targets US health care and biotechnology companies identified to have promising life sciences opportunities. LFSC was launched on Oct 31, 2024 and is issued by F/m Investments.
Asset Class Equity
Category Health
Region North America
Stock Exchange NASDAQ
Ticker Symbol LFSC
ETF Provider F/m Investments
Top 10 Holdings
54.64% of assets| Name | Symbol | Weight |
|---|---|---|
| Cogent Biosciences, Inc. | COGT | 8.21% |
| Travere Therapeutics, Inc. | TVTX | 7.00% |
| LivaNova PLC | LIVN | 6.62% |
| Spyre Therapeutics, Inc. | SYRE | 6.37% |
| Mirum Pharmaceuticals, Inc. | MIRM | 4.70% |
| Nektar Therapeutics | NKTR | 4.66% |
| United Therapeutics Corporation | UTHR | 4.51% |
| KalVista Pharmaceuticals, Inc. | KALV | 4.35% |
| US DOLLARS | n/a | 4.21% |
| TransMedics Group, Inc. | TMDX | 4.00% |
News
Emerald Advisers and F/m Investments Announce the Launch of the F/m Emerald Life Sciences Innovation ETF (LFSC)
LANCASTER, Pa.--(BUSINESS WIRE)--Emerald Advisers, in partnership with F/m Investments, today announces the launch of the F/m Emerald Life Sciences Innovation ETF (LFSC), now trading on the Nasdaq Sto...
1 year ago - Business Wire